CN1898211A - 喹啉化合物的晶形及其生产方法 - Google Patents

喹啉化合物的晶形及其生产方法 Download PDF

Info

Publication number
CN1898211A
CN1898211A CNA2004800389550A CN200480038955A CN1898211A CN 1898211 A CN1898211 A CN 1898211A CN A2004800389550 A CNA2004800389550 A CN A2004800389550A CN 200480038955 A CN200480038955 A CN 200480038955A CN 1898211 A CN1898211 A CN 1898211A
Authority
CN
China
Prior art keywords
crystal
compound
water
crystal form
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800389550A
Other languages
English (en)
Chinese (zh)
Inventor
小原義夫
高田泰孝
松本浩郎
吉田明広
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34736450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1898211(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of CN1898211A publication Critical patent/CN1898211A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800389550A 2003-12-26 2004-12-17 喹啉化合物的晶形及其生产方法 Pending CN1898211A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP431788/2003 2003-12-26
JP2003431788 2003-12-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201110198613.7A Division CN102321019B (zh) 2003-12-26 2004-12-17 喹啉化合物的晶形及其生产方法

Publications (1)

Publication Number Publication Date
CN1898211A true CN1898211A (zh) 2007-01-17

Family

ID=34736450

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2004800389550A Pending CN1898211A (zh) 2003-12-26 2004-12-17 喹啉化合物的晶形及其生产方法
CN201110198613.7A Expired - Lifetime CN102321019B (zh) 2003-12-26 2004-12-17 喹啉化合物的晶形及其生产方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201110198613.7A Expired - Lifetime CN102321019B (zh) 2003-12-26 2004-12-17 喹啉化合物的晶形及其生产方法

Country Status (21)

Country Link
US (19) US20070112024A1 (enExample)
EP (1) EP1697326B1 (enExample)
JP (7) JP5186108B2 (enExample)
KR (11) KR20190083674A (enExample)
CN (2) CN1898211A (enExample)
AT (1) ATE518835T1 (enExample)
AU (2) AU2004309241A1 (enExample)
CA (1) CA2551050C (enExample)
CY (1) CY1112464T1 (enExample)
DK (1) DK1697326T3 (enExample)
ES (1) ES2367172T3 (enExample)
IL (1) IL176470A (enExample)
MX (1) MX338019B (enExample)
NZ (1) NZ548041A (enExample)
PL (1) PL1697326T3 (enExample)
PT (1) PT1697326E (enExample)
RU (1) RU2370489C2 (enExample)
SI (1) SI1697326T1 (enExample)
TW (1) TWI328006B (enExample)
WO (1) WO2005063711A1 (enExample)
ZA (1) ZA200605658B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104507949B (zh) * 2012-09-27 2017-07-28 日产化学工业株式会社 高纯度的含氮杂环化合物的制造方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072040A1 (en) 2003-02-12 2004-08-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of pitavastatin calcium
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US7801272B2 (en) * 2007-09-28 2010-09-21 Rigaku Corporation X-ray diffraction apparatus and X-ray diffraction method
US20120022102A1 (en) * 2010-01-20 2012-01-26 Cadila Healthcare Limited Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof
KR101158517B1 (ko) 2010-04-29 2012-06-21 동방에프티엘(주) 고 순도 피타바스타틴 칼슘염 결정형 ａ의 제조방법
JP2013536219A (ja) * 2010-08-25 2013-09-19 カディラ・ヘルスケア・リミテッド ピタバスタチンカルシウムおよびその調製方法
WO2012063254A1 (en) 2010-11-12 2012-05-18 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
RU2452939C1 (ru) * 2011-01-18 2012-06-10 Закрытое акционерное общество "Научные приборы" Рентгенодифракционный способ идентификации партий фармацевтической продукции
ITMI20111475A1 (it) * 2011-08-02 2013-02-03 Dipharma Francis Srl Forme cristalline di pitavastatina sale di calcio
WO2013037838A1 (en) 2011-09-12 2013-03-21 Farma Grs, D.O.O. Polymorphic form of pitavastatin calcium
WO2013098773A1 (en) * 2011-12-28 2013-07-04 Dr. Reddy's Laboratories Limited Crystalline forms of pitavastatin calcium
JP5190159B1 (ja) * 2012-08-08 2013-04-24 興和株式会社 医薬
JP2014034574A (ja) * 2013-01-25 2014-02-24 Kowa Company Ltd 医薬
EP2970128B1 (en) * 2013-03-15 2019-12-04 Asieris Pharmaceutical Technologies Co., Ltd. Base addition salts of nitroxoline and uses thereof
CN105213319A (zh) * 2015-09-17 2016-01-06 青岛华之草医药科技有限公司 一种降血脂药物匹伐他汀钙组合物干混悬剂
JP2016222714A (ja) * 2016-09-20 2016-12-28 興和株式会社 医薬
TW202200547A (zh) * 2020-03-13 2022-01-01 印度商卡地拉保健有限公司 喹啉酮化合物的新穎鹽類
EP4308089A4 (en) * 2021-03-19 2025-02-26 Zydus Lifesciences Limited QUINOLONE COMPOUND IN SOLID FORMS AND PROCESSES FOR THEIR PREPARATION

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3175944A (en) * 1956-06-18 1965-03-30 Upjohn Co Dihydronovobiocin and derivatives thereof
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
GB8320521D0 (en) * 1983-07-29 1983-09-01 Glaxo Group Ltd Chemical process
JPS61171460A (ja) * 1985-01-23 1986-08-02 Dainippon Pharmaceut Co Ltd 塩酸メクロフエノキサ−ト１型結晶の製造法
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
JP2877366B2 (ja) 1988-08-25 1999-03-31 協和醗酵工業株式会社 結晶状ｌ−アスコルビン酸−２−リン酸ナトリウム塩の製造法
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
JPH0613526A (ja) 1992-06-25 1994-01-21 Seiko Epson Corp 半導体装置用リードフレーム及びその製造方法
JP2575590B2 (ja) * 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
FR2694558B1 (fr) 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
DE4235133A1 (de) 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
JP3623531B2 (ja) 1993-06-07 2005-02-23 ビーエーエスエフ アクチェンゲゼルシャフト 結晶質ｌ−アスコルビン酸−２−燐酸エステルマグネシウム塩の製造法
JP3558684B2 (ja) * 1994-06-28 2004-08-25 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の乾燥方法
NZ512207A (en) * 1999-01-14 2002-10-25 Nissan Chemical Ind Ltd Process for producing quinolinecarbaldehyde
CA2450820C (en) * 2001-08-16 2011-03-15 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
DE60326819D1 (de) * 2002-01-31 2009-05-07 Novartis Ag Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
US20050130978A1 (en) * 2002-04-17 2005-06-16 Masamichi Yuda Novel crystal of quinoxalinedione derivative anhydride
WO2004072040A1 (en) * 2003-02-12 2004-08-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of pitavastatin calcium
TWI328006B (en) 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104507949B (zh) * 2012-09-27 2017-07-28 日产化学工业株式会社 高纯度的含氮杂环化合物的制造方法

Also Published As

Publication number Publication date
JP2016029102A (ja) 2016-03-03
US20210053923A1 (en) 2021-02-25
US20180072676A1 (en) 2018-03-15
KR20180132973A (ko) 2018-12-12
RU2006127044A (ru) 2008-02-10
KR20170098976A (ko) 2017-08-30
IL176470A0 (en) 2006-10-05
KR20110017936A (ko) 2011-02-22
AU2011213742C1 (en) 2017-04-06
CY1112464T1 (el) 2015-12-09
AU2011213742B2 (en) 2014-05-15
WO2005063711A1 (en) 2005-07-14
KR20180040732A (ko) 2018-04-20
JP2018052988A (ja) 2018-04-05
KR20130014643A (ko) 2013-02-07
NZ548041A (en) 2010-04-30
US20090176987A1 (en) 2009-07-09
KR20200015826A (ko) 2020-02-12
PT1697326E (pt) 2011-09-12
EP1697326A1 (en) 2006-09-06
HK1095328A1 (en) 2007-05-04
US20200216395A1 (en) 2020-07-09
US20130204000A1 (en) 2013-08-08
US20120245200A1 (en) 2012-09-27
ES2367172T3 (es) 2011-10-31
MX338019B (es) 2016-03-29
IL176470A (en) 2011-10-31
US20140058109A1 (en) 2014-02-27
JP2012072175A (ja) 2012-04-12
US20220177433A1 (en) 2022-06-09
CA2551050C (en) 2020-06-02
RU2370489C2 (ru) 2009-10-20
JP5186108B2 (ja) 2013-04-17
US20170226061A1 (en) 2017-08-10
US20190367458A1 (en) 2019-12-05
KR20170010111A (ko) 2017-01-25
KR20190083674A (ko) 2019-07-12
US20110082298A1 (en) 2011-04-07
US20230322679A1 (en) 2023-10-12
ZA200605658B (en) 2007-11-28
JP2013136640A (ja) 2013-07-11
JP2017061536A (ja) 2017-03-30
ATE518835T1 (de) 2011-08-15
JP2014205719A (ja) 2014-10-30
TW200530186A (en) 2005-09-16
JP2007516952A (ja) 2007-06-28
KR20070001910A (ko) 2007-01-04
DK1697326T3 (da) 2011-09-19
US20190152916A1 (en) 2019-05-23
JP5267643B2 (ja) 2013-08-21
KR20160075844A (ko) 2016-06-29
CN102321019A (zh) 2012-01-18
US20110319624A1 (en) 2011-12-29
EP1697326B1 (en) 2011-08-03
KR20200130510A (ko) 2020-11-18
US20180297956A1 (en) 2018-10-18
SI1697326T1 (sl) 2011-11-30
CN102321019B (zh) 2016-06-08
US20140206719A1 (en) 2014-07-24
PL1697326T3 (pl) 2011-12-30
AU2011213742A1 (en) 2011-09-08
US20070112024A1 (en) 2007-05-17
TWI328006B (en) 2010-08-01
AU2004309241A1 (en) 2005-07-14
CA2551050A1 (en) 2005-07-14
US20150158816A1 (en) 2015-06-11
US20240294476A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
CN102321019B (zh) 喹啉化合物的晶形及其生产方法
CN1575287A (zh) 乙酰替苯胺衍生物的α型或β型结晶
JP2012072175A5 (enExample)
JP2007524569A (ja) ナテグリニドの結晶形
US7417165B2 (en) Crystalline forms of pregabalin
HK1040245B (zh) 玻璃状已知缓激肽拮抗剂
CN1291978C (zh) 5－羟基－1－甲基乙内酰脲的新型晶型
CN1950331A (zh) 那格列奈的多晶型物
US8754129B2 (en) Crystalline vorinostat form VI
CN100345846C (zh) 5－[4－[2－(n－甲基－n－(2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮的钠盐
CN1200930C (zh) 1－甲基－5－对甲苯酰吡咯－2－乙酰氨基乙酸愈创木酯(med 15)的新多晶形物
CN101048416A (zh) 有机化合物
HK1165417A (en) Crystal form of quinoline compound and process for its production
AU2013204129C1 (en) Crystal Form of Quinoline Compound and Process for its Production
WO2005108395A1 (en) Ziprasidone hydrochloride polymorph and process for its preparation
CN1688310A (zh) 加替沙星的新晶型
CN1694884A (zh) Ⅰ晶型、ⅱ晶型、ⅲ晶型泛昔洛韦及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070117